Topic: Compensation Package
Local employees have sent the company a 72-hour ultimatum, demanding a severance plan by Thursday.
Novartis needs to trace its ethics woes to their roots and apply its stated values to real-life decisions, experts say. Even then, change takes time.
While biopharma CEOs often catch the limelight for their multimillion-dollar paychecks, it is every diligent worker that forms a company—and some of them also get paid handsomely. Here, we rank the top 10 most generous biopharma companies by median employee pay in 2018.
If Allergan CEO Brent Saunders is let go after AbbVie’s $63 billion takeover of the California company goes through, he'll net a cool $38.7 million.
Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.
Being a top biopharma executive does have its perks—not the least of which is use of the company jet. Who topped 2018’s frequent flyer list?
If you thought Teva went big-time with CEO Kåre Schultz's 2017 pay package, check out his 2018 numbers—especially his $20 million cash bonus.
Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.
Ian Read stepped down as Pfizer's CEO in January, but the company is promising him a handsome payout for staying on board to counsel Albert Bourla.
Johnson & Johnson hit—and exceeded—all its financial goals in 2018. So why did its top executive take a $9 million-plus pay cut?